Oncos Therapeutics Overview
- Year Founded
-
2007
- Status
-
Acquired/Merged
- Employees
-
11
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$42.2M
Oncos Therapeutics General Information
Description
Developer of cancer therapies based on its oncolytic viruses. The company develops CGTG-102, an oncolytic adenovirus for the systemic stimulation of anti tumor immune response.
Contact Information
Website
www.oncos.comCorporate Office
- Saukonpaadenranta 2
- 00180 Helsinki
- Finland
Corporate Office
- Saukonpaadenranta 2
- 00180 Helsinki
- Finland
Oncos Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Merger/Acquisition | 02-Jul-2015 | $42.2M | Completed | Product Development | ||
| 2. Later Stage VC | 01-Jan-2014 | Completed | Product Development | |||
| 1. Early Stage VC | 29-Apr-2010 | $5.38M | $5.38M | Completed | Product Development |
Oncos Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Oncos Therapeutics Patents
Oncos Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2013076374-A1 | Recombinant serotype 5 (ac!5) adenoviral vectors | Inactive | 25-Nov-2011 | ||
| US-20150232811-A1 | Recombinant serotype 5 (ad5) adenoviral vectors | Active | 25-Nov-2011 | ||
| US-9410129-B2 | Recombinant serotype 5 (ad5) adenoviral vectors | Inactive | 25-Nov-2011 | ||
| WO-2013038066-A1 | Modified oncolytic vaccinia virus | Inactive | 16-Sep-2011 | ||
| AU-2011306846-A1 | Oncolytic adenoviral vectors and methods and uses related thereto | Active | 24-Sep-2010 | A61K48/0058 |
Oncos Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Oncos Therapeutics Former Investors (2)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| HealthCap | Venture Capital | Minority | ||
| Lifeline Ventures | Venture Capital | Minority |
Oncos Therapeutics FAQs
-
When was Oncos Therapeutics founded?
Oncos Therapeutics was founded in 2007.
-
Where is Oncos Therapeutics headquartered?
Oncos Therapeutics is headquartered in Helsinki, Finland.
-
What is the size of Oncos Therapeutics?
Oncos Therapeutics has 11 total employees.
-
What industry is Oncos Therapeutics in?
Oncos Therapeutics’s primary industry is Biotechnology.
-
Is Oncos Therapeutics a private or public company?
Oncos Therapeutics is a Private company.
-
What is the current valuation of Oncos Therapeutics?
The current valuation of Oncos Therapeutics is .
-
What is Oncos Therapeutics’s current revenue?
The current revenue for Oncos Therapeutics is .
-
How much funding has Oncos Therapeutics raised over time?
Oncos Therapeutics has raised $5.38M.
-
Who are Oncos Therapeutics’s investors?
HealthCap and Lifeline Ventures have invested in Oncos Therapeutics.
-
When was Oncos Therapeutics acquired?
Oncos Therapeutics was acquired on 02-Jul-2015.
-
Who acquired Oncos Therapeutics?
Oncos Therapeutics was acquired by Circio Holding.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
